MA
INO icon

MCF Advisors’s Inovio Pharmaceuticals INO Stock Holding History

MCF Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4K Hold
11,274
– – ﹤0.01% 1007
2026
Q1 		$19.6K Hold
11,274
– – ﹤0.01% 829
2025
Q4 		$19.6K Hold
11,274
– – ﹤0.01% 701
2025
Q3 		$26.4K Buy
+11,274
New +$21.6K ﹤0.01% 534
2022
Q3 		– Sell
-8
Closed – – 845
2022
Q2 		$0 Hold
8
– – ﹤0.01% 788
2022
Q1 		$0 Buy
+8
New +$360 ﹤0.01% 780
2021
Q4 		– Sell
-8
Closed -$1K – 348
2021
Q3 		$1K Hold
8
– – ﹤0.01% 694
2021
Q2 		$1K Buy
+8
New +$768 ﹤0.01% 564

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MCF Advisors's INO Position: Q2 2026 in Review

MCF Advisors held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 11,274 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

MCF Advisors first reported a position in INO in Q2 2021 and has held it in 8 quarters since. The position peaked at $26.4K in Q3 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • MCF Advisors held 11,274 shares of Inovio Pharmaceuticals worth $12.4K as of Q2 2026.
  • MCF Advisors left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1007 holding.
  • MCF Advisors first reported a position in Inovio Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
  • MCF Advisors's Inovio Pharmaceuticals position peaked at $26.4K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.